Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity

Cancer Research

Volumn 70, Issue 3, 2010, Pages 1101-1110

  Pavet, Valeria ^a   Beyrath, Julien ^b   Pardin, Christophe ^b   Morizot, Alexandre ^c,d   Lechner, Marie Charlotte ^b   Briand, Jean Paul ^b   Wendland, Miriam ^e   Maison, Wolfgang ^e   Fournel, Sylvie ^b   Micheau, Olivier ^c,d   Guichard, Gilles ^b,f   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CNRS   (France)

^c Chu   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; DEATH RECEPTOR 5; PROTEIN P53; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; STILBENES; SURFACE PLASMON RESONANCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76249094425     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2889     Document Type: Article

References (48)

1. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
2. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20.
3. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
4. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009;14:607-23.
5. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-57.
6. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007;11:1299-314.
7. Kuribayashi K, Krigsfeld G, Wang W, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008;7:2034-8.
8. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19-26.
9. In: Litwack G, editor. TRAIL. Academic Press; 2004.
10. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
11. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-61.
12. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
13. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-9.
14. Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004;199:437-48.
15. Teng MW, Westwood JA, Darcy PK, et al. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res 2007;67:7495-504.
16. Zerafa N, Westwood JA, Cretney E, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 2005;175:5586-90.
17. Altucci L, Rossin A, Hirsch O, et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res 2005;65:8754-65.
18. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680-6.
19. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-60.
20. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84.
21. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6.
22. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
23. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
24. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002;62:5800-6.
25. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomibinduced cell death. Br J Haematol 2005;130:501-10.
26. Motoki K, Mori E, Matsumoto A, et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005;11:3126-35.
27. Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41.
28. Grosse-Wilde A, Voloshanenko O, Bailey SL, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-10.
29. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-90.
30. Angell YM, Bhandari A, De Francisco MN, et al. Discovery and optimization of a TRAIL R2 agonist for cancer therapy. Adv Exp Med Biol 2009;611:101-3.
31. Li B, Russell SJ, Compaan DM, et al. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J Mol Biol 2006;361:522-36.
32. Scott FL, Stec B, Pop C, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009;457:1019-22.
33. Berg D, Lehne M, Muller N, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007;14:2021-34.
34. Poh TW, Huang S, Hirpara JL, Pervaiz S. LY303511 amplifies TRAILinduced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ 2007;14:1813-25.
35. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
36. Rink H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Lett 1987;28:3787-90.
37. Castro B, Dormoy JR, Evin G, Selve C. Reactifs de couplage peptidique I (1) - l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.). Tetrahedron Lett 1975;16:1219-22.
38. Humblet V, Misra P, Bhushan KR, et al. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem 2009;52:544-50.
39. Schneider P, Holler N, Bodmer JL, et al. Conversion of membranebound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-13.
40. Thomas LR, Johnson RL, Reed JC, Thorburn A. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem 2004;279:52479-86.
41. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90.
42. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-840.
43. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006;7:423-42.
44. Voltz E, Gronemeyer H. A new era of cancer therapy: cancer cell targeted therapies are coming of age. Int J Biochem Cell Biol 2008;40:1-8.
45. Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/ TRAIL receptor pathway. Int J Biochem Cell Biol 2007;39:280-6.
46. Finnberg N, El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008;7:1525-8.
47. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-72.
48. Trouche N, Wieckowski S, Sun W, et al. Small multivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. J Am Chem Soc 2007;129:13480-92.